Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
Tsuyoshi Otsuji,1 Yoshimi Nagai,2 Kenichiro Sho,1 Akiko Tsumura,1 Naoko Koike,1 Mei Tsuda,1 Tetsuya Nishimura,1 Kanji Takahashi2 1Department of Ophthalmology, Kansai Medical University, Takii Hospital, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical University, Hirakata Hospital, Osaka, J...
Guardado en:
Autores principales: | Otsuji T, Nagai Y, Sho K, Tsumura A, Koike N, Tsuda M, Nishimura T, Takahashi K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/39faaa2deaa44e92a4d7a740e4fe989e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019) -
Three-year results of a modified photodynamic therapy procedure (Ironing PDT) for age-related macular degeneration patients with large lesions
por: Otsuji T, et al.
Publicado: (2016) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Tryfon Rotsos, et al.
Publicado: (2010) -
Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Fujihara M, et al.
Publicado: (2012) -
Treatment of age-related macular degeneration: focus on ranibizumab
por: Martin S Spitzer, et al.
Publicado: (2008)